Smart Drug Delivery Systems Market

Smart Drug Delivery Systems Market (Product: Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-on Sensors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Smart Drug Delivery Systems Market Outlook 2031

  • The global smart drug delivery systems market was valued at US$ 8.7 Bn in 2022
  • The global market is projected to advance at a CAGR of 15.2% from 2022 to 2031
  • The global smart drug delivery systems market is anticipated to reach more than US$ 36 Bn by 2031

Analysts’ Viewpoint on Smart Drug Delivery Systems Market Scenario

Growth in prevalence of chronic diseases and rise in patient preference for advanced drug delivery systems are driving the global smart drug delivery systems (SDDS) market. Products facilitating self-medication are gaining traction across the globe, as medical technology developers attempt to make their offerings more patient-centric. Several key developments are expected to shape and transform the advanced drug delivery arena in the near future. Poor patient compliance is a serious issue that has ramifications in healthcare and the pharmaceutical industries as a whole. Noncompliance rates have not changed significantly in the last 25 years and are expected to further increase in the next few decades. Thus, market players are developing products that help ensure drugs achieve the desired therapeutic levels while avoiding the need for frequent administration. This enables patients to adhere to their drug regimens and thus improve compliance.

Smart Drug Delivery Systems Market

Smart Drug Delivery Systems Market Introduction

Smart drug delivery system or connected drug delivery system uses different approaches, formulations, technologies, and devices to deliver drugs to specific sites or targets. Drugs are released at proper rates at the sites of action in the process. Majority of the innovations in the pharmaceutical industry are motivated by the need to improve patient compliance. Drug formulators focusing on therapeutic areas need to pay close attention to patient experience in order to optimize adherence. Reduced dosage frequency and improved ease of administration are critical to providing the best possible experience for patients and encouraging adherence to their treatment regimen.

Thus, emerging therapeutics in SDDS are now turning into conventional modes of drug delivery to specific sites. Patients are shifting toward controlled drug delivery systems, as the healthcare sector's digitalization accelerates through the gradual integration of diagnostic point-of-care sensors and connected computation platforms into patients' daily routines. Internet of Things (IoT)-based devices such as wearable sensors can now measure functioning, respiration, biomarkers from sweat, and even an individual's emotional state. Metered dose inhalers, nebulizers, and dry powder inhalers are used for pulmonary drug delivery.

Nanotechnology plays a key role in the development of SDDS and early detection and personalized treatment of cancer. Limitations associated with traditional cancer therapy administration such as reduced drug solubility, chemo-resistance, systemic toxicity, narrow therapeutic indices, and poor oral bioavailability can be addressed using nanoparticle-based drug-delivery systems. Smart drugs in nanotechnology include targeted drug delivery and extended-release drug-delivery systems that offer additional ways to overcome these limitations. Recently, R&D of highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles gained prominence to provide SDDS with an extended drug release.

COVID-19 Impact on Global Smart Drug Delivery Systems Market

Extensive R&D activities are being undertaken on a global scale to combat COVID-19. Self-injection has gained popularity as a result of the pandemic, giving patients more power and control over their health and safety. Products in the smart drug delivery systems market enable better management of injection speed, injection site pain, and treatment anxiety during home healthcare.

Innovative therapies have been used for a long time to identify, treat, and manage respiratory and pulmonary conditions. However, the emergence of COVID-19 and a greater understanding of breathing issues and other health issues it can cause have led to an increase in production of cutting-edge digital devices and systems for respiratory and pulmonary care. Demand for asthma inhalers surged at the beginning of the COVID-19 pandemic. Additionally, autoinjectors are being developed to reduce the frequency of drug administration and support higher viscosity and concentrations. This is expected to improve adherence to suggested drug protocols. Thus, rise in cases of COVID-19 augments the demand for autoinjectors in the market.

Leading companies operating in the global smart drug delivery systems market are collaborating with tech companies to develop advanced products. In January 2022, Phillips-Medisize, a Molex company and a leader in drug delivery, diagnostic, and MedTech devices, partnered with SOTECH Health, a healthcare startup, to accelerate the development of a breath-sensor system that can detect COVID-19 in less than 30 seconds.

Rise in Demand for Wearable Injectors Fueling Connected Wearable Injectors Segment

In terms of product, the global smart drug delivery systems market has been classified into connected inhalers, connected autoinjectors, connected pen injectors, connected wearable injectors, add-on sensors, and others. The connected wearable injectors segment held the largest share of the market in 2021 and is expected to maintain its dominance during the forecast period. Growth of the segment can be ascribed to the rise in concerns over needle stick injuries, surge in geriatric population and prevalence of chronic diseases, and increase in demand for continuous health monitoring. According to the Centers for Disease Control and Prevention (CDC), approximately 385,000 injuries with contaminated needles and other sharps devices occur annually among hospital-based healthcare personnel. Injuries with contaminated needles and other sharp devices carry the risk of transmission of blood-borne viruses.

The connected autoinjectors segment is likely to grow significantly during the forecast period. Market players are launching new connected autoinjectors that improve patient experience. In May 2021, Phillips-Medisize, a Molex company, launched the Aria Smart Autoinjector platform to support medication management.

Better Patient Compliance Augmenting Adoption of Injectables

Based on delivery mode, the global smart drug delivery systems market has been segmented into injectable, inhalation, and oral. The injectable segment held substantial share of the market in 2021 due to benefits of injections such as better patient compliance, ease of application, and reduced dosage frequency and pain.

Increase in Prevalence of Diabetes and Cardiovascular Diseases Propelling Metabolic Disorders Segment

In terms of therapeutic area, the global smart drug delivery systems market has been classified into metabolic disorders, neurological disorders, respiratory disorders, hormonal disorders, and others. The metabolic disorders segment is anticipated to dominate the market during the forecast period, owing to the rise in prevalence of diabetes and cardiovascular diseases worldwide. According to the World Health Organization (WHO), about 422 million individuals across the globe are suffering from diabetes; most of these live in low-and middle-income countries. Furthermore, 1.5 million deaths are directly attributed to diabetes annually.

Growth in Number of Hospitals Across Globe

Based on end-user, the global smart drug delivery systems market has been segmented into hospitals, clinics, home care, ambulatory care settings, and others. The hospitals segment held the largest share of the market in 2021. This can be ascribed to the increase in number of hospitals and rise in adoption of smart drug delivery systems in these settings. According to the American Hospital Association (AHA), the number of hospitals in the U.S. rose from 5,564 in 2017 to 6,093 in 2022.

Regional Analysis of Global Smart Drug Delivery Systems Market

According to the smart drug delivery systems market analysis, North America dominated the global market in 2021 and is expected to maintain its position during the forecast period. Increase in R&D expenditure; rise in adoption of novel and improved devices; early availability of advanced technologies; growth in healthcare expenditure; and presence of sophisticated healthcare infrastructure and key market participants in the U.S. and Canada are driving the market in the region. Abbott Laboratories and Becton, Dickinson and Company have strong presence in the U.S.

According to the global smart drug delivery systems market forecast, Asia Pacific is expected to witness the fastest, double-digit growth due to the rise in geriatric population, increase in prevalence of cardiovascular diseases, expansion in healthcare infrastructure, and surge in medical tourism in the region. According to the Organization for Economic Cooperation and Development (OECD), India, Malaysia, Singapore, and Thailand are prominent medical tourism destinations in Asia Pacific.

Analysis of Key Players in Global Smart Drug Delivery Systems Market

The smart drug delivery systems market report concludes with the company profiles section that includes key information about major players in the market. Key players are focusing on product launches, mergers & acquisitions, partnerships, and collaborations to enhance their smart drug delivery systems market share. Abbott Laboratories, Adherium Ltd., Amiko Digital Health Limited, Becton, Dickinson and Company, BIOCORP, CeQur Corporation, Cognita Labs, E3D Elcam Drug Delivery Devices, H&T Presspart Manufacturing Ltd., HCmed Innovations Co., Ltd., Medtronic plc, Novo Nordisk, Phillips-Medisize, and Sonceboz are prominent players operating in the global market.

Key Developments in Global Smart Drug Delivery Systems Market

  • In March 2022, Novo Nordisk A/S launched NovoPen 6 and NovoPen Echo Plus — smart connected insulin pens available on prescription — in the U.K. for people with diabetes who use Novo Nordisk insulin
  • In December 2021, BIOCORP signed a new agreement with H&T Presspart (a division of Heitkamp & Thumann Group in Germany), under which the latter would sell and promote the former's InspairTM smart add-on device for metered-dose inhalers. The collaboration includes integration and commercialization of InspairTM, a smart sensor designed by BIOCORP that converts inhalers into connected devices to assist patients suffering from asthma or chronic obstructive pulmonary disease (COPD) in receiving their treatment.
  • In May 2021, the U.S. Food and Drug Administration approved The Bigfoot Unity Diabetes Management System, which incorporates smart pen caps for disposable insulin pens and injection devices the size of a marker that diabetics use to inject insulin. The system integrates with Abbott's FreeStyle Libre 2 technology. Abbott partnered with Bigfoot Biomedical to provide automated information that personalizes diabetes management.

Each of these players has been profiled in the smart drug delivery systems market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Smart Drug Delivery Systems Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 8.7 Bn

Market Forecast Value in 2031

More than US$ 36 Bn

Compound Annual Growth Rate (CAGR)

15.2%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Connected Inhalers
    • Connected Autoinjectors
    • Connected Pen Injectors
    • Connected Wearable Injectors
    • Add-on Sensors
    • Others
  • Drug Delivery Mode
    • Injectable
    • Inhalation
    • Oral
  • Therapeutic Area
    • Metabolic Disorders
    • Neurological Disorders
    • Respiratory Disorders
    • Hormonal Disorders
    • Others
  • End-user
    • Hospitals
    • Clinics
    • Home Care
    • Ambulatory Care Settings
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Abbott Laboratories
  • Adherium Ltd.
  • Amiko Digital Health Limited
  • Becton, Dickinson and Company
  • BIOCORP
  • CeQur Corporation
  • Cognita Labs
  • E3D Elcam Drug Delivery Devices
  • H&T Presspart Manufacturing Ltd.
  • HCmed Innovations Co., Ltd.
  • Medtronic plc
  • Novo Nordisk A/S
  • Phillips-Medisize
  • Sonceboz

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global smart drug delivery systems market in 2021?

The global smart drug delivery systems market was valued at US$ 8.7 Bn in 2021

How big will be the global smart drug delivery systems market by 2031?

The global smart drug delivery systems market is projected to reach more than US$ 36 Bn by 2031

What will be the CAGR of the global smart drug delivery systems market during the forecast period (2022–2031)?

The global smart drug delivery systems market is anticipated to advance at a CAGR of 15.2% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in patient preference for advanced drug delivery systems, growth in prevalence of chronic diseases, and advancements in smart drug delivery systems

What was the market share of the leading segment of the global smart drug delivery systems market?

The connected wearable injectors segment accounted for more than 54.0% share of the global smart drug delivery systems market in 2021

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global smart drug delivery systems market during the forecast period

Who are the prominent players in the global smart drug delivery systems market?

Abbott Laboratories, Adherium Ltd., Amiko Digital Health Limited, Becton, Dickinson and Company, BIOCORP, CeQur Corporation, Cognita Labs, E3D Elcam Drug Delivery Devices, H&T Presspart Manufacturing Ltd., HCmed Innovations Co., Ltd., Medtronic plc, Novo Nordisk A/S, Phillips-Medisize, and Sonceboz

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Smart Drug Delivery Systems Market

4. Market Overview

    4.1. Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

5. Key Insights

    5.1. Smart Insulin Pen - Brand Analysis

    5.2. Insulin Pen Delivery Devices Available in the U.S.

    5.3. Insights on Digitization of Diabetes: Opportunities & Challenges

    5.4. Key Industry Events (Partnership, Merger & Acquisition, etc.)

    5.5. COVID-19 Impact Analysis

6. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Product, 2017–2031

        6.3.1. Connected Inhalers

        6.3.2. Connected Autoinjectors

        6.3.3. Connected Pen Injectors

        6.3.4. Connected Wearable Injectors

        6.3.5. Add-on Sensors

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Product

7. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031

        7.3.1. Injectable

        7.3.2. Inhalation

        7.3.3. Oral

    7.4. Market Attractiveness Analysis, by Drug Delivery Mode

8. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        8.3.1. Metabolic Disorders

        8.3.2. Neurological Disorders

        8.3.3. Respiratory Disorders

        8.3.4. Hormonal Disorders

        8.3.5. Others

    8.4. Market Attractiveness Analysis, by Therapeutic Area

9. Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Key Findings/Developments

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Hospitals

        9.3.2. Clinics

        9.3.3. Home Care

        9.3.4. Ambulatory Care Settings

        9.3.5. Others

    9.4. Market Attractiveness Analysis, by End-user

10. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region, 2017–2031

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness By Country/Region

11. North America Smart Drug Delivery Systems Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product, 2017–2031

        11.2.1. Connected Inhalers

        11.2.2. Connected Autoinjectors

        11.2.3. Connected Pen Injectors

        11.2.4. Connected Wearable Injectors

        11.2.5. Add-on Sensors

        11.2.6. Others

    11.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031

        11.3.1. Injectable

        11.3.2. Inhalation

        11.3.3. Oral

    11.4. Market Value Forecast, by Therapeutic Area, 2017–2031

        11.4.1. Metabolic Disorders

        11.4.2. Neurological Disorders

        11.4.3. Respiratory Disorders

        11.4.4. Hormonal Disorders

        11.4.5. Others

    11.5. Market Value Forecast, by End-user, 2017–2031

        11.5.1. Hospitals

        11.5.2. Clinics

        11.5.3. Home Care

        11.5.4. Ambulatory Care Settings

        11.5.5. Others

    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Product

        11.7.2. By Drug Delivery Mode

        11.7.3. By Therapeutic Area

        11.7.4. By End-user

        11.7.5. By Country/Sub-region

12. Europe Smart Drug Delivery Systems Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product, 2017–2031

        12.2.1. Connected Inhalers

        12.2.2. Connected Autoinjectors

        12.2.3. Connected Pen Injectors

        12.2.4. Connected Wearable Injectors

        12.2.5. Add-on Sensors

        12.2.6. Others

    12.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031

        12.3.1. Injectable

        12.3.2. Inhalation

        12.3.3. Oral

    12.4. Market Value Forecast, by Therapeutic Area, 2017–2031

        12.4.1. Metabolic Disorders

        12.4.2. Neurological Disorders

        12.4.3. Respiratory Disorders

        12.4.4. Hormonal Disorders

        12.4.5. Others

    12.5. Market Value Forecast, by End-user, 2017–2031

        12.5.1. Hospitals

        12.5.2. Clinics

        12.5.3. Home Care

        12.5.4. Ambulatory Care Settings

        12.5.5. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Product

        12.7.2. By Drug Delivery Mode

        12.7.3. By Therapeutic Area

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product, 2017–2031

        13.2.1. Connected Inhalers

        13.2.2. Connected Autoinjectors

        13.2.3. Connected Pen Injectors

        13.2.4. Connected Wearable Injectors

        13.2.5. Add-on Sensors

        13.2.6. Others

    13.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031

        13.3.1. Injectable

        13.3.2. Inhalation

        13.3.3. Oral

    13.4. Market Value Forecast, by Therapeutic Area, 2017–2031

        13.4.1. Metabolic Disorders

        13.4.2. Neurological Disorders

        13.4.3. Respiratory Disorders

        13.4.4. Hormonal Disorders

        13.4.5. Others

    13.5. Market Value Forecast, by End-user, 2017–2031

        13.5.1. Hospitals

        13.5.2. Clinics

        13.5.3. Home Care

        13.5.4. Ambulatory Care Settings

        13.5.5. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Product

        13.7.2. By Drug Delivery Mode

        13.7.3. By Therapeutic Area

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Smart Drug Delivery Systems Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product, 2017–2031

        14.2.1. Connected Inhalers

        14.2.2. Connected Autoinjectors

        14.2.3. Connected Pen Injectors

        14.2.4. Connected Wearable Injectors

        14.2.5. Add-on Sensors

        14.2.6. Others

    14.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031

        14.3.1. Injectable

        14.3.2. Inhalation

        14.3.3. Oral

    14.4. Market Value Forecast, by Therapeutic Area, 2017–2031

        14.4.1. Metabolic Disorders

        14.4.2. Neurological Disorders

        14.4.3. Respiratory Disorders

        14.4.4. Hormonal Disorders

        14.4.5. Others

    14.5. Market Value Forecast, by End-user, 2017–2031

        14.5.1. Hospitals

        14.5.2. Clinics

        14.5.3. Home Care

        14.5.4. Ambulatory Care Settings

        14.5.5. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Product

        14.7.2. By Drug Delivery Mode

        14.7.3. By Therapeutic Area

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Product, 2017–2031

        15.2.1. Connected Inhalers

        15.2.2. Connected Autoinjectors

        15.2.3. Connected Pen Injectors

        15.2.4. Connected Wearable Injectors

        15.2.5. Add-on Sensors

        15.2.6. Others

    15.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031

        15.3.1. Injectable

        15.3.2. Inhalation

        15.3.3. Oral

    15.4. Market Value Forecast, by Therapeutic Area, 2017–2031

        15.4.1. Metabolic Disorders

        15.4.2. Neurological Disorders

        15.4.3. Respiratory Disorders

        15.4.4. Hormonal Disorders

        15.4.5. Others

    15.5. Market Value Forecast, by End-user, 2017–2031

        15.5.1. Hospitals

        15.5.2. Clinics

        15.5.3. Home Care

        15.5.4. Ambulatory Care Settings

        15.5.5. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Product

        15.7.2. By Drug Delivery Mode

        15.7.3. By Therapeutic Area

        15.7.4. By End-user

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)

    16.2. Market Share Analysis, by Company (2021)

    16.3. Company Profiles

        16.3.1. Abbott Laboratories

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Product Portfolio

            16.3.1.3. Financial Overview

            16.3.1.4. Strategic Overview

            16.3.1.5. SWOT Analysis

        16.3.2. Adherium Ltd.

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Product Portfolio

            16.3.2.3. Financial Overview

            16.3.2.4. Strategic Overview

            16.3.2.5. SWOT Analysis

        16.3.3. Amiko Digital Health Limited

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Product Portfolio

            16.3.3.3. Financial Overview

            16.3.3.4. Strategic Overview

            16.3.3.5. SWOT Analysis

        16.3.4. Becton, Dickinson and Company

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Product Portfolio

            16.3.4.3. Financial Overview

            16.3.4.4. Strategic Overview

            16.3.4.5. SWOT Analysis

        16.3.5. BIOCORP

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Product Portfolio

            16.3.5.3. Financial Overview

            16.3.5.4. Strategic Overview

            16.3.5.5. SWOT Analysis

        16.3.6. CeQur Corporation

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Product Portfolio

            16.3.6.3. Financial Overview

            16.3.6.4. Strategic Overview

            16.3.6.5. SWOT Analysis

        16.3.7. Cognita Labs

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Product Portfolio

            16.3.7.3. Financial Overview

            16.3.7.4. Strategic Overview

            16.3.7.5. SWOT Analysis

        16.3.8. E3D Elcam Drug Delivery Devices

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Product Portfolio

            16.3.8.3. Financial Overview

            16.3.8.4. Strategic Overview

            16.3.8.5. SWOT Analysis

        16.3.9. H&T Presspart Manufacturing Ltd.

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Product Portfolio

            16.3.9.3. Financial Overview

            16.3.9.4. Strategic Overview

            16.3.9.5. SWOT Analysis

        16.3.10. HCmed Innovations Co., Ltd.

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Product Portfolio

            16.3.10.3. Financial Overview

            16.3.10.4. Strategic Overview

            16.3.10.5. SWOT Analysis

        16.3.11. Medtronic plc

            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.11.2. Product Portfolio

            16.3.11.3. Financial Overview

            16.3.11.4. Strategic Overview

            16.3.11.5. SWOT Analysis

        16.3.12. Novo Nordisk

            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.12.2. Product Portfolio

            16.3.12.3. Financial Overview

            16.3.12.4. Strategic Overview

            16.3.12.5. SWOT Analysis

        16.3.13. Phillips-Medisize

            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.13.2. Product Portfolio

            16.3.13.3. Financial Overview

            16.3.13.4. Strategic Overview

            16.3.13.5. SWOT Analysis

        16.3.14. Sonceboz

            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.14.2. Product Portfolio

            16.3.14.3. Financial Overview

            16.3.14.4. Strategic Overview

            16.3.14.5. SWOT Analysis

List of Tables

Table 01: Smart Insulin Pen - Brand Analysis

Table 02: Insulin Pen Delivery Devices Available in the United States

Table 03: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 04: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017–2031

Table 05: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 06: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 07: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 08: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 09: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017–2031

Table 10: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 11: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 13: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 14: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017–2031

Table 15: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 16: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 19: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017–2031

Table 20: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 21: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 22: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 24: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017–2031

Table 25: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 26: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 27: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 28: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 29: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017–2031

Table 30: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 31: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 32: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 01: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031

Figure 03: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022–2031

Figure 04: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Inhalers, 2017–2031

Figure 05: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Autoinjectors, 2017-2031

Figure 06: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Pen Injectors, 2017-2031

Figure 07: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Wearable Injectors, 2017-2031

Figure 08: Global Smart Drug Delivery Systems Market (US$ Mn), by Add-on Sensors, 2017-2031

Figure 09: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031

Figure 10: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode 2021 and 2031

Figure 11: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022–2031

Figure 12: Global Smart Drug Delivery Systems Market (US$ Mn), by Injectable, 2017–2031

Figure 13: Global Smart Drug Delivery Systems Market (US$ Mn), by Inhalation, 2017-2031

Figure 14: Global Smart Drug Delivery Systems Market (US$ Mn), by Oral, 2017–2031

Figure 15: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031

Figure 16: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 17: Global Smart Drug Delivery Systems Market (US$ Mn), by Metabolic Disorders, 2017–2031

Figure 18: Global Smart Drug Delivery Systems Market (US$ Mn), by Neurological Disorders, 2017-2031

Figure 19: Global Smart Drug Delivery Systems Market (US$ Mn), by Respiratory Disorders, 2017-2031

Figure 20: Global Smart Drug Delivery Systems Market (US$ Mn), by Hormonal Disorders, 2017-2031

Figure 21: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031

Figure 22: Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 23: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022–2031

Figure 24: Global Smart Drug Delivery Systems Market (US$ Mn), by Hospitals, 2017–2031

Figure 25: Global Smart Drug Delivery Systems Market (US$ Mn), by Clinics, 2017-2031

Figure 26: Global Smart Drug Delivery Systems Market (US$ Mn), by Home Care, 2017–2031

Figure 27: Global Smart Drug Delivery Systems Market (US$ Mn), by Ambulatory Care Settings, 2017-2031

Figure 28: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031

Figure 29: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region, 2021 and 2031

Figure 30: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Region, 2022–2031

Figure 31: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031

Figure 33: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022–2031

Figure 34: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031

Figure 35: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022–2031

Figure 36: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031

Figure 37: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 38: North America Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 39: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022–2031

Figure 40: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Country, 2021 and 2031

Figure 41: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Country, 2022–2031

Figure 42: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017–2031

Figure 43: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031

Figure 44: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022–2031

Figure 45: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode. 2021 and 2031

Figure 46: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022–2031

Figure 47: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031

Figure 48: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 49: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 50: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022–2031

Figure 51: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 52: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 53: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017–2031

Figure 54: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031

Figure 55: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022–2031

Figure 56: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode 2021 and 2031

Figure 57: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022–2031

Figure 58: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031

Figure 59: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 60: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 61: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022–2031

Figure 62: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 63: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 64: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017–2031

Figure 65: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031

Figure 66: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022–2031

Figure 67: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031

Figure 68: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022–2031

Figure 69: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031

Figure 70: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 71: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 72: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022–2031

Figure 73: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 74: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 75: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017–2031

Figure 76: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031

Figure 77: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022–2031

Figure 78: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031

Figure 79: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022–2031

Figure 80: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031

Figure 81: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 82: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 83: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022–2031

Figure 84: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 85: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 86: Global Smart Drug Delivery Systems Market Share Analysis/Ranking, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved